Pipeline » MTR106 for Migraine
A promising preliminary open label study on 100 patients, carried out during 2001-2002, demonstrated the efficacy of MTR106 in alleviating Migraine attacks by standard end points routinely used for other state of the art medications. In the high dose group migraine relief was obtained within less than two hours, and no recurrent migraine attacks were observed. The effect on blood pressure and heart rate did not demonstrate any adverse reactions. The study proved that MTR-106 was effective in 73% of the patients. Similar studies conducted with various members from the Triptan family of drugs report a lower efficacy level.
Based on the conclusions from that study, a new immediate release oral tablet formulation has been developed. Meditor has succesfully completed a a Phase II Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in 40 migraine patients. The study was conducted under cGCP and assessed the pharmacokinetics and pharmacodynamics of MTR106 tablets for the treatment of acute migraine attacks without aura in Women.
